Table 5.
Per patient cost, effectiveness and cost-effectiveness of selected screening strategies
| Strategy | Cost per test UK£ (CNY) |
Difference in cost UK£ (CNY) |
True cases detected | Difference in true cases detected | ICER UK£ (CNY) per additional true case detected |
| C-SBQ | 2.22 (13.30) | – | 0.0858 | – | Dominated by microspirometry |
| Microspirometry | 1.60 (9.60) | −0.62 (−3.70) | 0.0883 | 0.0025 | 18.13 (108.78) vs no screening* |
| Peak flow | 1.71 (10.25) | 0.11 (0.64) | 0.0915 | 0.0057 | 32.89 (197.36) vs microspirometry |
| C-SBQ and microspirometry | 3.43 (20.59) | 1.72 (10.35) | 0.1184 | 0.0269 | 64.20 (385.20) vs peak flow |
*Due to the symptom-based question being excluded from the analysis, the next option is compared with no screening.
C-SBQ, Chinese Symptom-Based Questionnaire; ICER, incremental cost-effectiveness ratio.